Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

Código QR

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

Hong Liu-Seifert1, Bruce J Kinon1, Christopher J Tennant2, Jennifer Sniadecki1, Jan Volavka31Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA; 2CJT Biomedical Consulting, South Lake Tahoe, CA, USA; 3New York University, New York, NY, USAObjective: To...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong Liu-Seifert, Bruce J Kinon, Christopher J Tennant, Jennifer Sniadecki, Jan Volavka
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f8f07dff813c429bb02e706763cc4764
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan V, et al.
Publicado: (2011)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu X, et al.
Publicado: (2014)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
por: Takahiko Nagamine
Publicado: (2008)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
por: Jeffrey R Bishop, et al.
Publicado: (2008)

Risperidone improves interpersonal perception and executive function in patients with schizophrenia
por: Zhou Z, et al.
Publicado: (2016)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang X, et al.
Publicado: (2019)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louz&atilde; M, et al.
Publicado: (2011)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka M, et al.
Publicado: (2015)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone
por: Hongkaew Y, et al.
Publicado: (2015)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Adel Gabriel
Publicado: (2010)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
por: Hongyan Zhang, et al.
Publicado: (2011)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao Y, et al.
Publicado: (2013)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Dhiren Singh, et al.
Publicado: (2009)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Xinhua&nbsp;S Ren, et al.
Publicado: (2009)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao K, et al.
Publicado: (2013)

The efficacy of antipsychotics for prolonged delirium with renal dysfunction
por: Asano S, et al.
Publicado: (2017)

The influence of atypical antipsychotic drugs on sexual function
por: Just MJ
Publicado: (2015)

Altered heart rate dynamics associated with antipsychotic-induced subjective restlessness in patients with schizophrenia
por: Kim JH, et al.
Publicado: (2013)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
por: Mario Louz&atilde;, et al.
Publicado: (2010)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study
por: Gro&scaron;ić V, et al.
Publicado: (2014)

Risperidone-induced reversible neutropenia
por: Kattalai Kailasam V, et al.
Publicado: (2017)

Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia
por: Han JY, et al.
Publicado: (2017)

The NCAN gene: schizophrenia susceptibility and cognitive dysfunction
por: Wang P, et al.
Publicado: (2016)

What if it was easier to prevent schizophrenia than to treat it?
por: Kristen J. Brennand
Publicado: (2017)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari S, et al.
Publicado: (2015)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa T, et al.
Publicado: (2011)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
por: Shiraz Hussain, et al.
Publicado: (2021)

Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey
por: Olivares JM, et al.
Publicado: (2013)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
por: Okayasu H, et al.
Publicado: (2021)